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Objectives: To correlate the basal expression of complement regulatory proteins (CRPs) CD55,
CD59,  CD35, and CD46 in B-lymphocytes from the peripheral blood of a cohort of 10 patients
with rheumatoid arthritis (RA) initiating treatment with rituximab (RTX) with depletion and
time repopulation of such cells.
Methods: Ten patients with RA received two infusions of 1 g of RTX with an interval of
14  days. Immunophenotypic analysis for the detection of CD55, CD59, CD35, and CD46
on  B-lymphocytes was carried out immediately before the ﬁrst infusion. The population
of  B-lymphocytes was analyzed by means of basal CD19 expression and after 1, 2, and 6
months after the infusion of RTX, and then quarterly until clinical relapse. Depletion of
B-lymphocytes in peripheral blood was deﬁned as a CD19 expression <0.005 × 109/L.
Results: Ten women with a median of 49 years and a baseline DAS28 = 5.6 were evalu-
ated;  9 were seropositive for rheumatoid factor. Five patients showed a repopulation of
B-lymphocytes after 2 months, and the other ﬁve after 6 months. There was a correlation
between the basal expression of CD46 and the time of repopulation (correlation coefﬁ-
cient = −0.733, p = 0.0016). A similar trend was observed with CD35, but without statistical
signiﬁcance (correction coefﬁcient = −0.522, p = 0.12).
Conclusion: The increased CD46 expression was predictive of a faster repopulation of B-
lymphocytes in patients treated with RTX. Studies involving a larger number of patients
will be needed to conﬁrm the utility of basal expression of CRPs as a predictor of clinicalPlease cite this article in press as: Viecceli D, et al. Correlation between cellular expression of complement regulatory proteins with depletion
and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab. Rev Bras Reumatol. 2016.
http://dx.doi.org/10.1016/j.rbre.2016.09.007
response.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
∗ Corresponding author.
E-mail: daniviecceli@gmail.com (D. Viecceli).
ttp://dx.doi.org/10.1016/j.rbre.2016.09.007
255-5021/© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
ARTICLE IN PRESSRBRE-328; No. of Pages 7
2  r e v b r a s r e u m a t o l . 2 0 1 6;x  x x(x x):xxx–xxx
Correlac¸ão  entre  expressão  celular  de  proteínas  reguladoras  do
complemento  com  a  deplec¸ão  e  repopulac¸ão  de  linfócitos  B  no  sangue
periférico  de  pacientes  com  artrite  reumatoide  tratada  com  rituximabe
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Objetivos: Correlacionar a expressão basal das proteínas reguladoras do complemento (PRC)
CD55,  CD59, CD35 e CD46 nos linfócitos B do sangue periférico de uma coorte de 10 pacientes
com  artrite reumatoide (AR) iniciando tratamento com rituximabe (RTX) com a deplec¸ão e
tempo de repopulac¸ão dessas células.
Métodos: Dez pacientes com AR receberam duas infusões de 1g de RTX com intervalo de 14
dias.  Análises imunofenotípicas para detecc¸ão de CD55, CD59, CD35 e CD46 nos linfócitos
B  foram feitas imediatamente antes da primeira infusão. A populac¸ão de linfócitos B foi
analisada por meio da expressão de CD19 basal e após um, dois e seis meses após a infusão
de  RTX e então trimestralmente até a recaída clínica. Deplec¸ão de linfócitos B no sangue
periférico foi deﬁnida como expressão de CD19 < 0,005 × 109/l.
Resultados: Dez mulheres com mediana de 49 anos e DAS 28 basal de 5,6 foram avali-
adas;  nove eram soropositivas para o fator reumatoide. Cinco pacientes apresentaram
repopulac¸ão  de linfócitos B após dois meses e as outras cinco aos seis meses. Houve
correlac¸ão  entre a expressão basal de CD46 e o tempo de repopulac¸ão (coeﬁciente de
correlac¸ão  -0,733, p = 0,0016). Tendência semelhante foi observada com CD35, porém sem
signiﬁcância estatística (coeﬁciente de correc¸ão 0,522, p = 0,12).
Conclusão: Expressão aumentada de CD46 foi preditora de repopulac¸ão mais rápida de lin-
fócitos B em pacientes tratados com RTX. Estudos com um número maior de pacientes
serão necessários para conﬁrmar a utilidade da expressão basal das PRC como preditora de
resposta clínica.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Rheumatoid arthritis (RA) is an autoimmune disease that
affects about 1% of the adult population, with a prevalence
three times higher in women, that causes a chronic and
persistent polyarthritis, mainly of peripheral joints.1 The
inﬂammatory inﬁltrate composed of macrophages, CD4+ T-
cells, B-cells, dendritic cells, granulocytes and mast cells
leads to synovial proliferation, resulting in swollen and ten-
der joints, with high rates of functional limitation.2 High levels
of complement activation products such as membrane attack
complex (MAC), release of anaphylatoxins C3a and C5a, and
increased C3 and C4 consumption can be detected in the syno-
vial ﬂuid of patients with RA, suggesting an overactivation of
the complement system (CS) in these patients.3 Normal cells
are resistant to the complement-mediated lysis because they
have regulatory mechanisms consisting of soluble proteins in
biological ﬂuids, such as properdin and factor H, and anchored
to the membrane, such as CD55 (decay-accelerating factor
[DAF]), CD59 (membrane inhibitor of reactive lysis [MIRL]),
CD46 (membrane cofactor protein [MCP]) and CD35 (comple-
ment receptor type 1 [CR1]).4
Rituximab (RTX) is a chimeric monoclonal antibody
directed to CD20 which is expressed on the surface of pre-B-
cells to mature B-lymphocytes, leading to a transient, almostPlease cite this article in press as: Viecceli D, et al. Correlation between ce
and repopulation of B-lymphocytes in peripheral blood of patients with rh
http://dx.doi.org/10.1016/j.rbre.2016.09.007
complete, depletion of B-cells in blood and to a partial
depletion in bone marrow and in the synovial tissue.5–10 Its
mechanism of action is based on the signaling and subsequentBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
B-cell death by induction of apoptosis, complement-mediated
lysis, or cell death by macrophages.11,12 The clinical response
seems to correlate to the level of B-cell depletion in periph-
eral blood and synovium.6 The treatment of RA with RTX
showed signiﬁcant efﬁcacy in controlling signs and symptoms,
improving physical function, in addition to beneﬁts in the pre-
vention of radiological damage.13–19
Although a large number of patients present a satisfactory
response to treatment with RTX, about 40–50% are refractory
and the mechanism of this failure is not fully understood.5,18,19
In this context, the search for biomarkers that can predict
which subgroups of patients have the greatest potential to
be beneﬁted from this therapy has been one of the goals of
the most recent studies related to the drug. This strategy, in
addition to reducing costs, could minimize periods of disease
activity and of exposure to possible side effects of an ineffec-
tive treatment.20
Several studies have investigated the association between
increased expression of complement regulatory proteins
(CRPs) and the mechanism of treatment failure with RTX
in patients with lymphoproliferative disorders. Golay et al.
correlated the increased expression of CD55 and CD59 on
the surface of lymphoma tumor cells with increased resis-
tance to complement-mediated lysis.21 This same group, in
a study involving neoplastic cells isolated from patients withllular expression of complement regulatory proteins with depletion
eumatoid arthritis treated with rituximab. Rev Bras Reumatol. 2016.
chronic lymphocytic leukemia (CLL) and lymphoma, detected
a two-to-three-fold increase in cell lysis, when anti-CD55 and
anti-CD59 monoclonal antibodies were used.22 Other authors
have found an increased resistance to complement-mediated
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ysis triggered by RTX in the face of the increased expression
f CD5523 and CD59.24
Although the literature includes consistent ﬁndings sug-
esting that CRPs expression, particularly CD55 and CD59, can
e used as a biomarker of response to treatment with RTX on
ymphoproliferative diseases, no study in the literature has
ade this correlation in patients with RA.
The aim of this study is to correlate the basal expres-
ion of CRPs CD55, CD59, CD35, and CD46 on B lymphocytes
rom peripheral blood from a cohort of RA patients initiating
reatment with RTX with the depletion level of these cells in
eripheral blood and their time of repopulation. In this study,
he correlation between the expression of these proteins with
 clinical response will be evaluated, according to the Ameri-
an College of Rheumatology (ACR).
aterials  and  methods
tudy  population
e  included in this study 10 consecutive RA patients with
linical indication for initiation of treatment with RTX, accord-
ng to the guidelines of the Brazilian Society of Rheumatology
SBR): failure or intolerance to at least two schemes of tra-
itional disease-modifying drugs (DMARDs) and an anti-TNF
gent.25 The other inclusion criteria were: age under 18 years;
A diagnosis for at least 6 months according to ACR criteria1;
AS28 score (Disease Activity Score-28) greater ≥3.2; use of
n adequate contraception method to fertile patients; and
esire to participate voluntarily and ability to understand
he protocol, documented by the signing the Consent Form.
atients with overlapping of autoimmune rheumatic dis-
ase, lymphoproliferative disorders, and neoplastic diseases;
resence of active infection; use of cytotoxic drugs; seropos-
tivity for HIV, HBV, or HCV; active tuberculosis; allergy or
ypersensitivity to RTX; pregnant or breastfeeding women;
ubjects participating in another interventional clinical study;
V functional class deﬁned based on Steinbrocker functional-
ty criteria for RA26 and prior therapy with RTX. The patients
eceived two infusions of RTX 1 g separated by an interval
f 14 days. All patients were pretreated with methylpred-
isolone 100 mg,  paracetamol 1 g, and dexchlorpheniramine
 mg.  Patients were followed for a maximum period of 24
onths.
linical  assessment
ll patients underwent a baseline visit immediately before
he infusion of RTX, with a monthly visit 6 months after the
nfusions, and then quarterly. At each visit, routine laboratory
ests (blood count, transaminases, creatinine, routine uri-
alysis, erythrocyte sedimentation rate (ESR), and C-reactive
rotein) were carried out. On the ﬁrst visit, rheumatoid factor
RF), antinuclear (ANA) factor, complement, anti-HCV, anti-
IV, anti-HBc, and HBsAg serology, chest X-rays of hands andPlease cite this article in press as: Viecceli D, et al. Correlation between ce
and repopulation of B-lymphocytes in peripheral blood of patients with rh
http://dx.doi.org/10.1016/j.rbre.2016.09.007
eet, and a Mantoux test were also carried out. The follow-
ng clinical parameters were evaluated at each visit: counting
f 28 swollen and/or painful joints (always performed by the
ame examiner); overall score of disease activity (0–100 mm on 6;x  x x(x x):xxx–xxx 3
a visual analog scale [VAS] assigned by both the examiner and
the patient); a pain score (0–100 mm),  the Health Assessment
Questionnaire (HAQ) and DAS28 score using ESR.
Clinical  response  assessment
The clinical response to treatment was assessed 6 months
after infusion of RTX, being considered as positive when the
patient reached a response >20%, according to the criteria
established by ACR.27 A response failure was considered when
an only an improvement <20% was perceived, compared to
baseline parameters according to the same criteria. Clini-
cal relapse was considered when there was a loss of ACR20
response in patients considered responders.
Immunophenotypic  analysis
The analyses of peripheral blood ﬂow cytometry were per-
formed immediately before the ﬁrst infusion of RTX, and
1, 2 and 6 months after the 2nd infusion of RTX and after
quarterly intervals, according to a standardized technique in
leukocytes,28 during a period of fewer than 24 hours after
the collection. Brieﬂy, 100 L of whole blood were placed into
polystyrene tubes and stained with 8 L of each ﬂuorochrome-
conjugated monoclonal antibody to CD19-PerCP, CD55PE,
CD59FITC, CD35PE, and CD46FITC (BD Biosciences, San Diego,
CA, USA). After incubation, 1.0 mL of FACSlyse (BD Biosciences,
San Diego, CA, USA) was added, and lysis was allowed dur-
ing 10 min  at room temperature. Samples were washed and
resuspended in 0.5 mL of phosphate buffered saline (PBS)
and analyzed in CellQuestTM software of FACSCalibur ﬂow
cytometer – BD (Becton Dickinson). The intensity of the
membrane ﬂuorescence was calculated from the mean ﬂuo-
rescence intensity (MFI). The deﬁnition of positive or negative
cells was deﬁned when the staining of control isotype was
performed in order to deﬁne the gates and to distinguish a
positive staining versus autoﬂuorescence or of nonspeciﬁc
antibody binding. In each of these collections, CD19-marked
cells were quantiﬁed. The expression of CD55, CD59, CD35,
and CD46 was investigated before the infusion of RTX, only in
CD19+ subpopulations.
100,000 events in the region of lymphocytes by ﬂow cytom-
etry were acquired. Data were analyzed with Inﬁnicyt software
in the region of lymphocytes (in terms of relative values and
of ﬂuorescence intensity); to do so, we used data from routine
blood counts to calculate the absolute values.
B-cell depletion in peripheral blood was deﬁned by a value
of CD19+ <0.005 × 109/L of total leukocytes. B-cell repopu-
lation was deﬁned when the concentration of B-cells was
>0.005 × 109/L of total leukocytes.
Statistical  analysis
Due to the lack of previous studies evaluating CRPs expres-
sion and B-lymphocyte depletion and repopulation after RTX
in patients with RA, we chose a pilot cohort of 10 patients whollular expression of complement regulatory proteins with depletion
eumatoid arthritis treated with rituximab. Rev Bras Reumatol. 2016.
would provide the necessary information for a more  accurate
calculation of sample size in subsequent studies to conﬁrm
the observations of this study, in the case of some association
trend.
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Data were analyzed using the SPSS 16.0 program for Win-
dows. In order to compare the means of the parametric values,
the Student’s t-test for paired samples the Mann–Whitney test
for nonparametric values were performed. Correlations were
analyzed using the Pearson test for parametric data and the
Spearman correlation for nonparametric data. The correlation
was considered as statistically signiﬁcant with a p-value <0.05,
and clinically signiﬁcant when a correlation coefﬁcient >0.4
was obtained.
Ethical  aspects
This study was approved by the HCPA Research Ethics Com-
mittee under number 09–585 and was funded through the
Fundo de Apoio à Pesquisa e Eventos (FIPE) of HCPA. All partici-
pating patients signed an Informed Consent Term. The Roche
Laboratory contributed with a donation of RTX for use in 10
patients through a research initiative protocol, without inter-
ference in the design, analysis and preparation of this study.
ResultsPlease cite this article in press as: Viecceli D, et al. Correlation between ce
and repopulation of B-lymphocytes in peripheral blood of patients with rh
http://dx.doi.org/10.1016/j.rbre.2016.09.007
In total, 10 female patients with a median of 49 years were
included in this study. Their baseline characteristics are
shown in Table 1. The median for disease duration was 8 years.
All patients were being medicated with methotrexate (median
Table 1 – Baseline characteristics of patients taking
rituximab.
RA
patients
(n  = 10)
Age (years), median (range) 49 (37–56)
Female gender, n (%) 10 (100)
White, n (%) 8 (80)
Positive rheumatoid factor, n (%) 9 (90)
Disease duration (years), median (range) 8 (2–18)
Erosions, n (%) 8 (80)
ESR (mm/h), median (range) 27.5 (8–120)
CRP (mg/L), median (range) 10.8 (4–42.2)
HAQ (0–3), median (range) 1 (0.750–2.125)
DAS28-ESR, median (range) 5.6 (4.4–6.82)
Current use of MTX, n (%) 10 (100)
MTX dose (mg/week), median (range) 25 (20–25)
Current use of corticosteroids, n (%) 10 (100)
Prednisone dose (mg/day), median (range) 10 (5–15)
Anti-TNF, previous, n (%)
1 9 (90)
≥1 1 (10)
Anti-TNF used, n (%)
Adalimumab 5 (50)
Etanercept 2 (20)
Golimumab 1 (10)
Inﬂiximab 3(30)
RA, rheumatoid arthritis; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; HAQ, Health Assesment Questionnaire; DAS28-
ESR, Disease Activity Score in 28 joints using the erythrocyte
sedimentation rate; MTX, methotrexate.
Range = minimum and maximum values found. 1 6;x  x x(x x):xxx–xxx
25 mg/week) and prednisone (median 10 mg/day); in addition,
these patients had made use of at least one anti-TNF agent.
Nine patients (90%) were RF-positive and 8 of them (80%) had
joint erosions.
In evaluating the clinical response, 8 patients (80%) reached
ACR20 four months after infusion of RTX; but only 3 (30%)
maintained this response after 6 months. When considering
the DAS28 activity index, four months after infusion of RTX 3
patients (30%) had clinical remission, 2 patients (20%) showed
low clinical activity, and 5 patients (50%) showed moderate
disease activity. In the evaluation performed 6 months after
infusion of RTX, only 1 patient (10%) exhibited low clinical
activity.
The repopulation of B-cells in peripheral blood was identi-
ﬁed in the analysis carried out 2 months after infusion of RTX
in 5 patients (50%), and in the other patients at the time of the
6-month analysis.
Table 2 shows the median of CD55, CD59, CD35, and CD46
expressions, as measured by MFI  in B-cells of the whole group
of patients and of subsets with repopulation identiﬁed in 2
and 6 months. Patients with repopulation of B lymphocytes
in the peripheral blood at 2 months showed an increased
expression of CD46 (median of MFI = 72) compared to those
with repopulation at 6 months (median of MFI  = 47), con-
ﬁrming a correlation between an increased expression of CD46
with an earlier repopulation of B lymphocytes in the periph-
eral blood (correlation coefﬁcient = −0733, p = 0.016). A similar
trend was found with CD35, but with no statistical signiﬁcance
(median of MFI = 444 for patients with earlier repopulation
versus MFI = 289 for those with a later repopulation, with a
correlation coefﬁcient = −0522, p = 0:12). No correlations were
found between the expressions of CD55 and CD59 on B lym-
phocytes and the time of repopulation of B lymphocytes in
this sample of patients (correlation coefﬁcients = −0383 and
−0174, and p = 0.275 and 0.631, respectively).
Although a variation in the expression of CD55, CD59, CD35,
and CD46 on B lymphocytes of the patients studied has been
observed, we  found no correlation between this expression
and the clinical response measured by ACR20 at 6 months. The
expressions of CRPs measured by the median of MFI  among
responders (CD59 = 39; CD55 = 456; CD35 = 444; and CD46 = 79)
were not statistically different compared to non-responders
(CD59 = 40; CD55 = 322; CD35 = 346; and CD46 = 49). These data
are presented in Table 3.
Discussion
In this study, we detected a correlation between an increased
expression of CD46 and earlier repopulation of B-lymphocytes
in peripheral blood following the treatment with RTX. A sim-
ilar trend with CD35 was observed, but with no statistical
signiﬁcance. This association supports the hypothesis that
an increased expression of CD46 could reduce complement-
mediated lysis, one of the mechanisms of action of RTX, thus
reducing the effectiveness of the drug. However, there was nollular expression of complement regulatory proteins with depletion
eumatoid arthritis treated with rituximab. Rev Bras Reumatol. 2016.
correlation between the expression of CRPs in B lymphocytes
and clinical response. Contrary to the expected biological rea-
soning that the patients with an increased expression of CRPs
in peripheral B-lymphocytes treated with RTX would have an
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Table 2 – Correlation between baseline expression of CD55, CD59, CD35, and CD46 in B-lymphocytes before treatment
with rituximab and repopulation time of these cells.
Antigen Total, n = 10 B-cell repopulation Correlation coefﬁcient p-Value
MFI median (range)a 2 months, n = 5 6 months, n = 5
MFI median (range)a MFI median (range)a
CD59 39.5 (27–66) 40 (29–66) 39 (27–44) −0.174 0.631
CD55 386.5 (148–619) 430 (148–619) 322 (276–456) −0.383 0.275
CD35 353.5 (148–557) 444 (240–557) 289 (148–429) −0.522 0.122
CD46 52.5 (36–137) 72 (49–137) 47 (36–53) −0.733 0.016b
MFI, mean of ﬂuorescence intensity.
a Range between minimum and maximum values found.
b p < 0.05 = statistically signiﬁcant.
Table 3 – Correlation between baseline expression of CD55, CD59, CD35, and CD46 in B-cells before treatment with
rituximab and clinical response at 6 months.
Antigen Clinical response at 6 months (ACR20) p-Value
Responders, n = 3 Nonresponders, n = 7
MFI median (range)a MFI median (range)a
CD59 39 (29–66) 40 (27–60) 1.0
CD55 456 (430–619) 322 (148–551) 0.067
CD35 444 (289–456) 346 (148–557) 0.383
CD46 79 (53–137) 49 (36–72) 0.067
e
t
s
t
b
t
p
p
b
C
t
t
t
l
w
r
O
t
t
y
a
c
e
h
r
t
C
e
tMFI, mean of ﬂuorescence intensity.
a Range between minimum and maximum values found.
arlier lymphoid repopulation and a lower clinical response to
herapy, in our study, we found a tendency for higher expres-
ion of CD46 and CD55 on peripheral lymphocytes B of patients
hat reached ACR20 at 6 months, compared to nonresponders,
ut without statistical signiﬁcance (p = 0.067). We believe that
his seemingly contradictory ﬁnding is due to the small sam-
le size leading to a lack of power of this study, in order to
roperly evaluate this outcome. This limitation also proba-
ly affected the results that showed no correlation between
D55 and CD59 expression on peripheral B lymphocytes with
he earlier repopulation of these cells in peripheral blood after
reatment with RTX.
Another important issue in this study was the low sus-
ained response rate at 6 months (30%). This response was
ower than previous studies evaluating patients with RA
hose prior anti-TNF treatment failed,18,19 where ACR20
esponses were obtained at a mean of about 50% at 6 months.
ur sample, when compared to the populations studied in
hese studies, had lower rates of HAQ (1.0 × 1.8–1.9, respec-
ively), DAS28 (5.6 × 6.8), and disease duration (8 years × 10–12
ears), but used higher doses of methotrexate (25 mg  × 15 mg)
nd glucocorticoids. All our patients were taking glucocorti-
oids, while only 65% used this drug class in the study of Cohen
t al.19 We  do not know, however, whether these differences
ave inﬂuenced somehow our results.
Despite the limitations related to sample size and the low
ate of therapeutic response at 6 months, this is the ﬁrst study
o correlate the expression of CRPs of CD55, CD59, CD35, andPlease cite this article in press as: Viecceli D, et al. Correlation between ce
and repopulation of B-lymphocytes in peripheral blood of patients with rh
http://dx.doi.org/10.1016/j.rbre.2016.09.007
D46 with the repopulation time of B lymphocytes in periph-
ral blood and clinical response in a cohort of RA patients
reated with RTX. Previous studies of lymphoproliferativediseases had already hypothesized that an increased expres-
sion of CRPs could reduce the complement-mediated
cytotoxicity and inﬂuence in the response to treatment with
RTX.21,23,24,29 These studies have involved in vitro models, ani-
mals, and humans. Dalle et al. investigated the expression
of CD55, CD59, and CD46 in rats that received cells derived
from human follicular lymphoma and detected an increased
expression of CD59 in those animals with RTX-resistant
lymphoma.24 Terui et al. studied the expression of CD55
in non-Hodgkin’s Lymphoma (NHLs) cells from 30 patients,
showing that this protein contributed to the resistance to
complement-mediated cytotoxicity and to the resistance to
RTX.23 Although there is evidence that CRPs may have a
response-biomarker role to RTX in lymphoproliferative dis-
eases, this association has never been studied in patients with
RA.
Our ﬁndings reinforce the importance of further studies to
evaluate the role of variation in CRPs in the depletion of B
lymphocytes and their impact on the therapeutic efﬁcacy of
RTX, ideally involving more  numerous cohorts of RA patients.
The potential for the clinical signiﬁcance of this correlation
can only extrapolate the prediction of therapeutic response
since, the combination of RTX with CRP inhibitors, such
as recombinant protein Ad35KK++ and anti-CD55 and anti-
CD59 monoclonal antibodies could be taken into account.
This combination has been studied in lymphoproliferative
diseases using in vitro models and animals, with favorable
responses. The use of anti-CD55 and anti-CD59 increased thellular expression of complement regulatory proteins with depletion
eumatoid arthritis treated with rituximab. Rev Bras Reumatol. 2016.
complement-mediated cytotoxicity, increasing the sensitivity
of tumor cells to the action of RTX.22,30–32 In a recent study,
Beyer et al. studied the use of a pretreatment with Ad35K++ (a
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recombinant protein which induces CD46 internalization and
degradation) in monkeys treated with subclinical RTX, observ-
ing a complete cell depletion of peripheral B lymphocytes.33
We  can conclude that the increase of CD46 expression in B
lymphocytes from RA patients can predict an earlier repopu-
lation of such cells in the peripheral blood of patients treated
with RTX. Further studies are needed to conﬁrm this result
and to evaluate the correlation of other CRPs with repopula-
tion and clinical response to treatment, thus enabling the use
of these proteins as biomarkers of response to RTX.
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